Sunday 18 October 2026
Export FHTX’s income statement to Excel — free account
Foghorn Therapeutics Inc.
FHTX Healthcare Biotechnology
Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024. In the quarter to June 2026, revenue grew 112.7%, EPS grew 64.3% and free cash flow grew 14.9%, each against the same quarter a year earlier.
1.85
0.04
−2.12%
Follow FHTX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 5 | 2 | 1 | 2 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 0.26 | 0.81 | (0.93) | (2.22) | (2.62) | (4.46) |
P/S ratio |
— | — | — | 0.00 | 644.51 | 14.06 | 7.93 | 11.46 | 11.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | 1.93 | 2.47 | (0.15) | (3.97) | (4.76) | (10.28) |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 1.41 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | (21.02) | 71.55 | (9.35) | (9.83) | (10.57) | (15.27) |
P/B ratio |
— | — | — | 1.53 | 8.78 | 2,413.79 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | 1.53 | 8.78 | 2,413.79 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | 0.00 | 542.63 | (2.89) | 1.66 | 1.56 | 6.47 |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.48 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | (1.85) | (14.24) | (0.29) | (0.48) | (0.35) | (2.32) |
EV/FCF |
— | — | — | (1.22) | (13.36) | (0.29) | (0.47) | (0.35) | (2.32) |
Quick Ratio |
— | 11.57 | 1.23 | 9.86 | 3.17 | 6.26 | 4.01 | 3.64 | 2.68 |
Current Ratio |
— | 11.68 | 1.33 | 10.12 | 9.44 | 6.37 | 4.11 | 3.73 | 2.73 |
Net Debt/EBITDA |
— | (1.49) | 0.09 | 2.47 | 1.59 | 3.00 | 2.19 | 2.34 | 1.88 |
Debt/Assets |
0.00% | 181.80% | 49.06% | 7.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (1.99) | (7.45) | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.10 | 0.08 | 0.13 |
Operating CF/Net income |
— | 0.86 | 0.91 | 0.45 | 0.50 | (1.78) | 1.20 | 1.16 | 1.16 |
Capex/Depreciation |
— | 0.00 | (1.39) | (12.02) | (0.97) | (0.60) | (1.53) | 0.61 | (0.04) |
Interest Coverage |
— | (140.43) | (94.60) | (70.00) | (52.85) | (20.64) | — | — | — |
| — | 41.38% | 80.33% | (236.54%) | (83.37%) | (224.54%) | 255.39% | 141.17% | 96.45% | |
| — | (122.33%) | (156.35%) | (49.51%) | (26.13%) | (23.55%) | (28.50%) | (30.40%) | (30.82%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (67.47%) | (739.27%) | (35.95%) | (23.65%) | (34.95%) | (50.55%) | (44.98%) | (70.47%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 13,422.09% | 6,089.84% | 549.29% | 321.15% | 418.23% | 276.51% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 2,615.35% | 1,647.31% | 159.91% | 94.78% | 125.47% | 89.13% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 688.60% | 635.63% | 74.56% | 47.39% | 52.62% | 33.64% |
Graham Net Nets |
— | — | — | 0.36 | 0.04 | (0.20) | (0.45) | (0.31) | (0.42) |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 9.84 | 5.55 | 6.73 |
Earnings Yield |
— | — | — | (30.72%) | (11.94%) | (40.31%) | (36.28%) | (34.96%) | (21.67%) |
Free Cash Flow Yield |
— | — | — | (21.09%) | (6.30%) | 71.17% | (44.08%) | (39.10%) | (25.33%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.04 | 0.04 | 0.46 | 0.81 | 0.41 | 0.49 |
Operating CF per Share |
— | (0.62) | (11.05) | (2.83) | (1.35) | 4.66 | (2.81) | (1.83) | (1.37) |
Capex per Share |
— | 0.00 | (0.23) | (1.44) | (0.09) | (0.03) | (0.03) | (0.02) | 0.00 |
Free Cash Flow per Share |
— | (0.62) | (11.28) | (4.27) | (1.44) | 4.63 | (2.84) | (1.85) | (1.37) |
Cash per Share |
— | 1.09 | 3.70 | 16.82 | 4.15 | 8.31 | 5.58 | 4.44 | 2.54 |
Shareholders Equity per Share |
— | (1.07) | (0.35) | 13.23 | 2.61 | 0.00 | (1.84) | (0.83) | (1.72) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (1.07) | (0.35) | 13.23 | 2.61 | 0.00 | (1.84) | (0.83) | (1.72) |
Free Cash Flow |
— | (22.65) | (47.30) | (47.22) | (53.56) | 192.40 | (119.33) | (101.31) | (86.15) |
Working Capital |
— | 36.94 | 4.23 | 171.84 | 410.87 | 296.19 | 181.75 | 182.61 | 103.50 |
Capital Expenditures |
— | (1.54) | (0.96) | (15.93) | (3.31) | (1.21) | (1.22) | (0.91) | (0.05) |
Net Current Asset Value |
— | (41.93) | (6.93) | 81.28 | 36.66 | (53.37) | (122.92) | (79.91) | (143.37) |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.47 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 37.05 | 2.51 | 0.06 | 0.04 | 0.04 | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.18 | 0.26 | 0.07 | 0.19 | 0.13 | 0.06 | (0.15) | 0.73 |
Cash ROIC |
— | (28.66%) | (189.12%) | (13.43%) | (21.33%) | 55.62% | (76.07%) | (51.11%) | (166.81%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 1,939.60 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 2.73 | 2.73 | 3.56 | 3.75 | 4.62 | 5.84 | 5.02 | 4.03 |
Average Assets |
— | 21.53 | 32.70 | 138.97 | 387.68 | 462.33 | 345.40 | 284.95 | 241.04 |
Average Common Equity |
— | (63.64) | (63.64) | 29.09 | 121.53 | 48.49 | (38.54) | (61.36) | (77.01) |
Columns are period end dates